Revenue
No reported data
ArriVent BioPharma, Inc. (AVBP)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Research & development | $153.4M | $79.0M | $64.9M |
| Operating expenses | $177.5M | $94.3M | $74.6M |
| Operating income | −$177.5M | −$94.3M | −$74.6M |
| Net income | −$166.3M | −$80.5M | −$69.3M |
| Basic EPSper diluted share | -$4.32 | -$2.56 | -$32.38 |
| Diluted EPSper diluted share | -$4.32 | -$2.56 | -$32.38 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 10, 2025Form 4 | HHLR ADVISORS, LTD. +1TenPercentOwner | SellCommon Stock · indirect | 555.6K | $23.37 | $12.98M | 3.93M |